If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
67
results.
Updated on
19/05/2024 [06:45:00]
Absstract of: WO2024100188A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Absstract of: US2024156962A1
A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.
Absstract of: AU2022381186A1
Provided herein are methods of treating a subject who has multiple myeloma and has received prior treatment and has limited treatment options. Infusions of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 10
Absstract of: WO2024102484A1
The disclosed technology relates to methods for improved risk stratification of Acute Myeloid Leukemia (AML.) patients, and more particularly, for improved risk stratification of adult and pediatric AML patients using inflammation gene signatures (iScore).
Absstract of: WO2024102361A1
A pharmaceutical combination includes a beta-lactam antibiotic alone or in combination with a beta-lactamase inhibitor useful for treating multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. A method for treating multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma includes administering to a patient in need thereof an effective amount of a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor. Beta-lactam antibiotic for use in combination with a beta-lactamase inhibitor for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma in a patient in need of the treatment is also described.
Absstract of: WO2024100250A1
In a first aspect, the invention relates to a combination of at least one menin inhibitor with at least one immunoproteasome inhibitor for use as medicament, preferably for use in the treatment of leukemia. A second aspect of the invention is related to a pharmaceutical preparation comprising at least one menin inhibitor and at least one immunoproteasome inhibitor, optionally one or more pharmaceutically acceptable carrier(s) and optionally one or more pharmaceutically acceptable adjuvant(s).
Absstract of: US2024158529A1
CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.
Absstract of: US2024159757A1
In one embodiment, a method of building an optimized color flow high parameter reagent 20-color panel for detection of aberrant cells in acute myeloid leukemia (AML) is disclosed using a full spectrum flow cytometer. In another embodiment, a reagent kit for detection of aberrant cells in acute myeloid leukemia (AML) is disclosed for use with a full spectrum flow cytometer.
Absstract of: AU2021471006A1
The present invention relates to the treatment of subjects having relapsed and/or refractory (R/R) follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having R/R FL by administering a combination of mosunetuzumab and lenalidomide.
Absstract of: US2024159763A1
The disclosure provides methods and materials for detecting endogenous IgA antibodies to one or more, or all, of OmpC (ACA), Ki67 (AKiA), TK1, integrin (AINTA) and keratin (AKERA), which are useful to diagnose and distinguish chronic enteropathies, e.g. gastrointestinal neoplasms, e.g., gastrointestinal lymphoma, and, inflammatory conditions, e g inflammatory bowel disease, in felines.
Absstract of: US2024156872A1
The present disclosure provides methods of treating disease and disorders of the hematological system. The disclosure provides a method of expanding a population of hematopoietic stem cells (HSCs) while maintaining the population in an undifferentiated state comprising contacting the population of HSCs in the presence of a CMA activator for a period of time until a sufficient number of HSCs is obtained thereby producing an expanded HSC population.
Absstract of: WO2024102946A2
Pharmaceutical compositions and methods for using boron-based ligands of enolases to treat cancer are disclosed. One such pharmaceutical composition includes a therapeutically effective amount of a ligand of enolase (1) having a general formula III or a pharmaceutically acceptable derivative thereof. The cancer can be a carcinoma, sarcoma, lymphoma, leukemia, or melanoma. The cancer can be prostate cancer.
Absstract of: US2024156816A1
Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.
Absstract of: WO2024102067A1
Provided herein is an antigen-binding protein that specifically binds and/or detects the transmembrane activator and calcium-modulator and cyclophilin ligand (CAML) interactor (TACI) / TNFRSF13B, wherein the antigen binding protein comprises a CDR sequence having GFSITSDYA (SEQ ID NO: 1) for CDRH1, ISYSGST (SEQ ID NO: 2) for CDRH2, ARVVSTSFDS (SEQ ID NO: 3) for CDRH3, ESVDNYGISF (SEQ ID NO: 4) for CDRL1, VAS (SEQ ID NO: 5) for CDRL2, and QQSKEVPYT (SEQ ID NO: 6) for CDRL3, or having amino acid sequences that are at least 85% identical to the sequences, or sequences having 1 or 2 amino acids different from the sequences thereof. Also provided herein are polynucleotides, vectors, and host cells thereof. Further provided herein are pharmaceutical compositions and methods of treating a disease, such as TACI-positive multiple myeloma.
Absstract of: EP4368185A1
In a first aspect, the invention relates to a combination of at least one menin inhibitor with at least one immunoproteasome inhibitor for use as medicament, preferably for use in the treatment of leukemia. A second aspect of the invention is related to a pharmaceutical preparation comprising at least one menin inhibitor and at least one immunoproteasome inhibitor, optionally one or more pharmaceutically acceptable carrier(s) and optionally one or more pharmaceutically acceptable adjuvant(s).
Absstract of: TW202317084A
The present invention relates to a particularly advantageous new therapeutic use of melflufen (melphalan flufenamide; L-melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof: in the treatment or prophylaxis of multiple myeloma in a patient having multiple myeloma who: - has not received a stem cell transplant; or - has received a stem cell transplant that was at least 5 years ago; or - is 75 years old or older; or - has not received a stem cell transplant and is 75 years old or older, or has received a stem cell transplant that was at least 5 years ago and is 75 years old or older; or - has received a stem cell transplant and the disease subsequently progressed at least 36 months after the transplant. The inventors have found that melflufen, and in particular melflufen in combination with dexamethasone, is surprisingly effective for the treatment or prophylaxis of multiple myeloma in these patients. More particularly, the present inventors have found that melflufen demonstrates superior anti-neoplastic activity in comparison to other treatments for multiple myeloma in these patient populations.
Absstract of: EP4368189A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Absstract of: EP4368641A2
The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.
Absstract of: WO2024097981A1
Disclosed are methods for the diagnosing and staging of cancers including, but not limited to multiple myeloma and treatment regimens incorporating said methods.
Absstract of: WO2024097758A1
Provided herein are methods of treating acute leukemia, such as acute myeloid leukemia (AML), in an individual, such as an individual having a mutation within the nucleophosmin 1 (NPM1) gene or a rearrangement within the lysineK-methyltransferase 2A (KMT2A) gene, wherein the methods comprise administering a menin inhibitor, ziftomenib, to the individual at a dose of 600 milligrams daily.
Absstract of: WO2024097876A1
A method of determining the likelihood that a subject with acute myeloid leukemia (AML) will respond to a treatment is provided. The method comprises detecting the levels of protein biomarkers in a biological sample obtained from a human subject. Subjects determined to have a high likelihood of responding to therapy comprising a hypomethylating agent and a BCL-2 inhibitor, such as Venetoclax, conventional chemotherapy, conventional chemotherapy and an additional therapy, or an alternative therapy can be selected to continue or initiate the treatment, while subjects determined to have a low likelihood of responding can discontinue treatment and/or be administered an alternative therapy. Methods of treating AML patients are also provided, as are kits and systems for biomarker detection, recordation, and responder status determination.
Absstract of: WO2024094741A1
The present invention relates to combination therapies employing an anti-CD20/anti-CD3 bispecific antibody in combination with an anti-CD19/anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist and the use of these combination therapies for the treatment of B-cell cancer such as diffuse large B cell lymphoma (DLBCL).
Absstract of: WO2024095174A1
Disclosed provides a method of treating measure residue disease (MRD) in a subject with cancer using an allogeneic leukemia-derived cell as a vaccine based on the information provided by prognostic biomarkers comprising dendritic cells including cDC1 cDC2, and/or pDC; CD8+ T cells including CD8+CD45RA+ cells, CD8+ CD45RA- CCR7+ CM T cells, and/or CD8 RO+ T cells; B cells; NK cells including CD56++ NK cells and/or CD56+ NK cells; CD4 CD161+ T cells; CD14+CD16- non-inflammatory monocytes, or any combination thereof.
Absstract of: WO2024098001A1
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as melanoma, non-small cell lung cancer, and chronic myeloid leukemia (CML).
Nº publicación: WO2024097905A1 10/05/2024
Applicant:
CELGENE CORP [US]
CELGENE CORPORATION
Absstract of: WO2024097905A1
Provided herein are adoptive cell therapy methods involving the administration of genetically engineered cells followed by an immunomodulatory agent maintenance therapy for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM), such as high risk multiple myeloma or newly diagnosed multiple myeloma (NDMM). In some embodiments, the methods are for treating subjects who experienced an early relapse, an inadequate response or a suboptimal response after frontline autologous stem cell transplant therapy (ASCT).
BOPI
Electronic site
